142 related articles for article (PubMed ID: 31110935)
1. Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model.
Kun Z; Xin G; Tao W; Chenglong Z; Dongsheng W; Liang T; Tielong L; Jianru X
J Bone Oncol; 2019 Jun; 16():100238. PubMed ID: 31110935
[TBL] [Abstract][Full Text] [Related]
2. EDIL3 influenced the αvβ3-FAK/MEK/ERK axis of endothelial cells in psoriasis.
Niu X; Han Q; Li X; Li J; Liu Y; Li Y; Wu Y; Zhang K
J Cell Mol Med; 2022 Oct; 26(20):5202-5212. PubMed ID: 36065978
[TBL] [Abstract][Full Text] [Related]
3. The extracellular matrix protein Edil3 stimulates osteoblast differentiation through the integrin α5β1/ERK/Runx2 pathway.
Oh SH; Kim JW; Kim Y; Lee MN; Kook MS; Choi EY; Im SY; Koh JT
PLoS One; 2017; 12(11):e0188749. PubMed ID: 29182679
[TBL] [Abstract][Full Text] [Related]
4. EDIL3 promotes epithelial-mesenchymal transition and paclitaxel resistance through its interaction with integrin α
Gasca J; Flores ML; Jiménez-Guerrero R; Sáez ME; Barragán I; Ruíz-Borrego M; Tortolero M; Romero F; Sáez C; Japón MA
Cell Death Discov; 2020; 6():86. PubMed ID: 33014430
[TBL] [Abstract][Full Text] [Related]
5. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
6. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor (EGF)-Like Repeats and Discoidin I-Like Domains 3 (EDIL3): A Potential New Therapeutic Tool for the Treatment of Keloid Scars.
Ryu YH; Lee YJ; Kim KJ; Lee SJ; Han YN; Rhie JW
Tissue Eng Regen Med; 2017 Jun; 14(3):267-277. PubMed ID: 30603483
[TBL] [Abstract][Full Text] [Related]
8. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
[TBL] [Abstract][Full Text] [Related]
9. EDIL3/Del-1 prevents aortic dissection through enhancing internalization and degradation of apoptotic vascular smooth muscle cells.
Yin Z; Zhang J; Zhao M; Liu J; Xu Y; Peng S; Pan W; Wei C; Zheng Z; Liu S; Qin JJ; Wan J; Wang M
Autophagy; 2024 Jul; ():1-21. PubMed ID: 38873925
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer.
Liu D; You M; Xu Y; Li F; Zhang D; Li X; Hou Y
Int Immunopharmacol; 2016 Oct; 39():265-272. PubMed ID: 27497194
[TBL] [Abstract][Full Text] [Related]
11. Identification of EDIL3 on extracellular vesicles involved in breast cancer cell invasion.
Lee JE; Moon PG; Cho YE; Kim YB; Kim IS; Park H; Baek MC
J Proteomics; 2016 Jan; 131():17-28. PubMed ID: 26463135
[TBL] [Abstract][Full Text] [Related]
12. EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade.
Tabasum S; Thapa D; Giobbie-Hurder A; Weirather JL; Campisi M; Schol PJ; Li X; Li J; Yoon CH; Manos MP; Barbie DA; Hodi FS
Cancer Immunol Res; 2023 Nov; 11(11):1493-1507. PubMed ID: 37728484
[TBL] [Abstract][Full Text] [Related]
13. Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment.
Sceneay J; Griessinger CM; Hoffmann SHL; Wen SW; Wong CSF; Krumeich S; Kneilling M; Pichler BJ; Möller A
PLoS One; 2018; 13(4):e0196040. PubMed ID: 29677215
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction.
Danilin S; Merkel AR; Johnson JR; Johnson RW; Edwards JR; Sterling JA
Oncoimmunology; 2012 Dec; 1(9):1484-1494. PubMed ID: 23264895
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs).
Nam S; Lee A; Lim J; Lim JS
Biomol Ther (Seoul); 2019 Jan; 27(1):63-70. PubMed ID: 30521746
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic and immunological role of EDIL3 in human tumours: From pan-cancer analysis to validation in gastric cancer.
Ke B; Jin P; Wang XJ; Liu N; Liang H; Zhang RP
Heliyon; 2024 Jun; 10(11):e32291. PubMed ID: 38882287
[TBL] [Abstract][Full Text] [Related]
17. Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice.
Abedi-Valugerdi M; Wolfsberger J; Pillai PR; Zheng W; Sadeghi B; Zhao Y; Hassan M
Int Immunopharmacol; 2016 Nov; 40():41-49. PubMed ID: 27580414
[TBL] [Abstract][Full Text] [Related]
18. miR-34a expands myeloid-derived suppressor cells via apoptosis inhibition.
Huang A; Zhang H; Chen S; Xia F; Yang Y; Dong F; Sun D; Xiong S; Zhang J
Exp Cell Res; 2014 Aug; 326(2):259-66. PubMed ID: 24780820
[TBL] [Abstract][Full Text] [Related]
19. Rab7 GTPase controls lipid metabolic signaling in myeloid-derived suppressor cells.
Ding X; Zhang W; Zhao T; Yan C; Du H
Oncotarget; 2017 May; 8(18):30123-30137. PubMed ID: 28415797
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitor rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease after bone marrow transplantation.
Lin Y; Wang B; Shan W; Tan Y; Feng J; Xu L; Wang L; Han B; Zhang M; Yu J; Yu X; Huang H
Clin Immunol; 2018 Feb; 187():122-131. PubMed ID: 29132870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
